Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
aheadofprint
Résumé
The uncertain treatment duration for nucleos(t)ide analogues (NA) used in the treatment of chronic hepatitis B (CHB) is an important problem for both patients and physicians. The aim of this study was to evaluate the determinants of virologic relapse (VR) and the optimum time of treatment discontinuation in the follow-up of CHB patients who voluntarily discontinued treatment after virological suppression was achieved under NA use. Data from 138 patients from 11 centers were included in this registry-based study. Factors associated with VR were investigated using multivariate Cox regression analysis. Ninety-nine (71.7%) of the patients were HBeAg (Hepatitis B e antigen) negative. During the 24-month follow-up period after treatment discontinuation, VR occurred in 58.7% (n = 81) of all patients and 57.6% (n = 57) of HBeAg-negative patients. The duration of NA treatment was significantly shorter (cutoff 60 months) in HBeAg-negative patients who later developed VR. In addition, the duration of virologic remission achieved under NA treatment was significantly shorter (cutoff 52 months) in those who later developed VR. In the Cox multivariate regression model of HBeAg-negative patients, having less than 60 months of NA treatment (HR = 2.568; CI:1.280-5.148; P = 0.008) and the levels of alanine aminotransferase being equal to or higher than twice the upper level of normal at the beginning of treatment (HR = 3.753; CI:1.551-9.081; P = 0.003) were found to be statistically significant and independently associated with VR. The findings of this study may provide clinical guidance in terms of determining the most appropriate discontinuation time for NA.
Identifiants
pubmed: 38407855
doi: 10.1097/MEG.0000000000002722
pii: 00042737-990000000-00300
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661–662.
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370–398.
Hsu YC, Yeh ML, Wong GLH, Chen CH, Peng CY, Buti M, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis 2021; 224:1890–1899.
Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepat Med 2022; 14:87–100.
Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 2016; 63:1481–1492.
Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, et al. Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: A prospective stop study. J Infect Dis 2017; 215:581–589.
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, et al. Improving the prediction of relapse after Nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B. Clin Infect Dis 2021; 73:e892–e903.
Huang CW, Yang CT, Su PY, Chen YY, Huang SP, Yen HH. Chronic hepatitis B relapse rates after cessation of tenofovir alafenamide and entecavir therapy. Biomedicines 2023; 11:752.
Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019; 49:218–228.
Zu Siederdissen CH, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e antigen-negative patients. J Infect Dis 2018; 218:1480–1484.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, et al. Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther 2018; 23:677–685.
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, et al. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021; 9:313–322.
van Bömmel F, Berg T. Risks and benefits of discontinuation of Nucleos(t)ide analogue treatment: a treatment concept for patients with Hbeag-negative chronic hepatitis B. Hepatology Communications 2021; 5:1632–1648.
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 1049; 185:92.
Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34:344–352.
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021; 56:856–867.
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, et al. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27:1497–1506.
Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, et al. Outcomes of cessation of antiviral therapy in chronic hepatitis b: A retrospective cohort study. Medeni Med J 2021; 36:201–208.
Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, et al.; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018; 47:1170–1180.
Zhang H, Chen F, Giang E, Bao F, Lauer GM, Marsh C, et al. Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy. Antivir Ther 2021; 26:3–8.
Tekin S. When to stop antiviral therapy in chronic hepatitis B. Klimik Dergisi 2019; 32:4–7.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560–1599.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Vol 10. Hepatol Int 2016; 10:1–98.
Deǧertekin H, Güneş G. Horizontal transmission of hepatitis B virus in Turkey. Public Health 2008; 122:1315–1317.
Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok ASF. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012; 19:205–212.
Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat 2013; 20:536–549.